WO2014079464A1 - Nouvelles compositions enzymatiques pour le traitement d'une infection par le virus de l'immunodéficience humaine (vih) - Google Patents

Nouvelles compositions enzymatiques pour le traitement d'une infection par le virus de l'immunodéficience humaine (vih) Download PDF

Info

Publication number
WO2014079464A1
WO2014079464A1 PCT/EG2012/000033 EG2012000033W WO2014079464A1 WO 2014079464 A1 WO2014079464 A1 WO 2014079464A1 EG 2012000033 W EG2012000033 W EG 2012000033W WO 2014079464 A1 WO2014079464 A1 WO 2014079464A1
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
reverse transcriptase
pharmaceutical compositions
enzyme
treatment
Prior art date
Application number
PCT/EG2012/000033
Other languages
English (en)
Inventor
Sherif Salah Abdul Aziz
Nada Sherif Salah ABDUL AZIZ
Original Assignee
Sherif Salah Abdul Aziz
Abdul Aziz Nada Sherif Salah
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sherif Salah Abdul Aziz, Abdul Aziz Nada Sherif Salah filed Critical Sherif Salah Abdul Aziz
Priority to PCT/EG2012/000033 priority Critical patent/WO2014079464A1/fr
Publication of WO2014079464A1 publication Critical patent/WO2014079464A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Definitions

  • HIV Human Immunodeficiency Virus
  • This invention relates to a novel inhibitors for retroviral protease, More particularly, the invention is concerned with formation of immune antibodies against the viral enzymes of human immunodeficiency virus (HIV) .As such this antibodies have potential use for the treatment of acquired immune deficiency virus syndrome and other retroviruses
  • HIV human immunodeficiency virus
  • This invention relates to a novel inhibitors for retroviral protease, More particularly, the invention is concerned with formation of immune antibodies against the viral enzymes of human immunodeficiency virus (HIV) .As such this antibodies have potential use for the treatment of acquired immune deficiency virus syndrome and other retroviruses
  • HIV human immunodeficiency virus
  • HIV human immunodeficiency vims
  • AIDS acquired immunodeficiency syndrome
  • the instant invention discuses die causes of susceptibility to infection with HIV
  • DNA polymerase enzyme is the main enzyme for processes of viral replication and producing new viron.
  • the invention depend on how we can induce our immune cells to produce antibodies against some enzymes compatible with our system 5-
  • This invention stimulates the immune cells to stin ting in formation by voluntary mechanism the switch off antibodies which protect our immune cell from over consuming.
  • the instant invention introduced novel DNA polymerase inhibitors which can enhance the effect of anticancer drugs and antiviral drugs.
  • Plate 1-1 explain the mechanism of HIV pathophysiology and process of treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention concerne l'utilisation d'enzymes bifonctionnelles pour présenter des anticorps de neutralisation à spectre extrêmement large, les rendant ainsi un agent antiviral potentiel efficace contre le virus de l'immunodéficience humaine (VIH).
PCT/EG2012/000033 2012-11-21 2012-11-21 Nouvelles compositions enzymatiques pour le traitement d'une infection par le virus de l'immunodéficience humaine (vih) WO2014079464A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/EG2012/000033 WO2014079464A1 (fr) 2012-11-21 2012-11-21 Nouvelles compositions enzymatiques pour le traitement d'une infection par le virus de l'immunodéficience humaine (vih)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EG2012/000033 WO2014079464A1 (fr) 2012-11-21 2012-11-21 Nouvelles compositions enzymatiques pour le traitement d'une infection par le virus de l'immunodéficience humaine (vih)

Publications (1)

Publication Number Publication Date
WO2014079464A1 true WO2014079464A1 (fr) 2014-05-30

Family

ID=47388475

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EG2012/000033 WO2014079464A1 (fr) 2012-11-21 2012-11-21 Nouvelles compositions enzymatiques pour le traitement d'une infection par le virus de l'immunodéficience humaine (vih)

Country Status (1)

Country Link
WO (1) WO2014079464A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997004105A1 (fr) * 1995-07-14 1997-02-06 University Of Washington Adn-polymerase de virus d'herpes gamma associes a la maladie de kaposi et a la fibromatose retroperitoneale
WO2000061766A2 (fr) * 1999-04-09 2000-10-19 Biomira, Inc. Vaccin anticancereux specifique de la telomerase
WO2002070679A2 (fr) * 2001-03-02 2002-09-12 Gemvax As Vaccins
US20040247613A1 (en) * 1997-04-18 2004-12-09 Geron Corporation Treating cancer using a telomerase vaccine
US20080175861A1 (en) * 2006-12-22 2008-07-24 The Penn State Research Foundation Modified polymerases and attenuated viruses and methods of use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997004105A1 (fr) * 1995-07-14 1997-02-06 University Of Washington Adn-polymerase de virus d'herpes gamma associes a la maladie de kaposi et a la fibromatose retroperitoneale
US20040247613A1 (en) * 1997-04-18 2004-12-09 Geron Corporation Treating cancer using a telomerase vaccine
WO2000061766A2 (fr) * 1999-04-09 2000-10-19 Biomira, Inc. Vaccin anticancereux specifique de la telomerase
WO2002070679A2 (fr) * 2001-03-02 2002-09-12 Gemvax As Vaccins
US20080175861A1 (en) * 2006-12-22 2008-07-24 The Penn State Research Foundation Modified polymerases and attenuated viruses and methods of use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHIBA J ET AL: "Generation of neutralizing antibody to the reverse transcriptase of human immunodeficiency virus type 1 by immunizing of mice with an infectious vaccinia virus recombinant", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 207, no. 1, 22 August 1997 (1997-08-22), pages 53 - 60, XP027447300, ISSN: 0022-1759, [retrieved on 19970822], DOI: 10.1016/S0022-1759(97)00104-X *
KLUTCH M ET AL: "Generation of HIV-1/HIV-2 cross-reactive peptide antisera by small sequence changes in HIV-1 reverse transcriptase and integrase immunizing peptides.", 1998, JOURNAL OF BIOMEDICAL SCIENCE 1998, VOL. 5, NR. 3, PAGE(S) 192 - 202, ISSN: 1021-7770, XP009171614 *

Similar Documents

Publication Publication Date Title
Perreau et al. Targeted immune interventions for an HIV-1 cure
CA1326450C (fr) Modulation des manifestations associees au virus du sida au moyen d'arn a double brin
US20230310594A1 (en) Methods of treating a latent hiv-1 infection using non-coding deoxyribonucleic acids
Khalid et al. HIV and messenger RNA (mRNA) vaccine
RU2007115549A (ru) Вакцины на основе инактивированного цельного вируса совместимого субтипа для лечения пациентов с вич-инфекцией
Fritsch et al. The role of STING signaling in central nervous system infection and neuroinflammatory disease
Fortner et al. mRNA-based vaccine technology for HIV
Nolan Harnessing viral devices as pharmaceuticals: Fighting HIV-1's fire with fire
WO2014079464A1 (fr) Nouvelles compositions enzymatiques pour le traitement d'une infection par le virus de l'immunodéficience humaine (vih)
Kolata How remdesivir, new hope for Covid-19 patients, was resurrected
WO2007137591A3 (fr) Vaccin contre le vih
Trobia et al. Effects of drug resistance in the tumour-immune system with chemotherapy treatment
DE60140950D1 (de) Neuer gentherapeutischer wirkstoff zur behandlung g
KR101426996B1 (ko) 테트라케라 스캔덴스 에탄올 추출물을 유효성분으로 포함하는 항바이러스 조성물 및 이의 용도
RU2765589C9 (ru) Способ лечения вич
WO2016156920A1 (fr) Procédé de fabrication d'un médicament à base de plantes au moyen d'une enzyme de l'estomac du moustique pour le traitement de virus et du sida
RU2261105C1 (ru) Способ профилактики клещевого энцефалита
CN111154755B (zh) 一种双链寡核苷酸dna及其应用
JP2022151441A (ja) 筋炎と筋膜炎の治療薬。
Saifullah et al. The CRISPR-Cas9 induced CCR5 Δ32 mutation as a potent gene therapy methodology for resistance to HIV-1 variant: a review.
Dwivedi et al. Anti-HIV therapy: pipeline approaches and future directions
WO2004066954A3 (fr) Composition therapeutique destinee au traitement du virus hiv-1 et hiv-2
WO2020170263A1 (fr) Médicament pour le traitement de la rage
Schneider et al. Problems and prospects of gene therapy against HIV
KR20070050934A (ko) Ｔ-세포 조절에 의한 ｈｉｖ 감염의 치료 방법

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12803504

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12803504

Country of ref document: EP

Kind code of ref document: A1